A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Necrobiosis Lipoidica Clinical Trial

Official title:
An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Status Completed

Clinical Trial Summary

This is an open-label study that will evaluate the safety of PCS499 for the treatment of necrobiosis lipoidica (NL) and will inform the design of future studies. Approximately 12 NL patients (6-9 patients without ulceration and 3-6 patients with ulceration) who also meet other inclusion/exclusion criteria will be enrolled in the study. The primary objective of this study is to evaluate the safety and tolerability profile of PCS499 in patients with Necrobiosis Lipoidica.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Necrobiosis Lipoidica

Clinical Trial Details

NCT number	NCT03698864
Study type	Interventional
Source	Processa Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	November 7, 2018
Completion date	February 25, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04492618` - Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica	Phase 2
	Terminated	`NCT04800562` - A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica	Phase 2